348 related articles for article (PubMed ID: 26669800)
1. ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease.
Shibuya Y; Chang CC; Chang TY
Future Med Chem; 2015; 7(18):2451-67. PubMed ID: 26669800
[TBL] [Abstract][Full Text] [Related]
2. ACAT1 as a Therapeutic Target and its Genetic Relationship with Alzheimer's Disease.
Alavez-Rubio JS; Juarez-Cedillo T
Curr Alzheimer Res; 2019; 16(8):699-709. PubMed ID: 31441726
[TBL] [Abstract][Full Text] [Related]
3. Acyl-coenzyme A:cholesterol acyltransferase 1 blockage enhances autophagy in the neurons of triple transgenic Alzheimer's disease mouse and reduces human P301L-tau content at the presymptomatic stage.
Shibuya Y; Niu Z; Bryleva EY; Harris BT; Murphy SR; Kheirollah A; Bowen ZD; Chang CCY; Chang TY
Neurobiol Aging; 2015 Jul; 36(7):2248-2259. PubMed ID: 25930235
[TBL] [Abstract][Full Text] [Related]
4. Acute ACAT1/SOAT1 Blockade Increases MAM Cholesterol and Strengthens ER-Mitochondria Connectivity.
Harned TC; Stan RV; Cao Z; Chakrabarti R; Higgs HN; Chang CCY; Chang TY
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982602
[TBL] [Abstract][Full Text] [Related]
5. Cellular pregnenolone esterification by acyl-CoA:cholesterol acyltransferase.
Rogers MA; Liu J; Kushnir MM; Bryleva E; Rockwood AL; Meikle AW; Shapiro D; Vaisman BL; Remaley AT; Chang CCY; Chang TY
J Biol Chem; 2012 May; 287(21):17483-17492. PubMed ID: 22474282
[TBL] [Abstract][Full Text] [Related]
6. Acat1 knockdown gene therapy decreases amyloid-β in a mouse model of Alzheimer's disease.
Murphy SR; Chang CC; Dogbevia G; Bryleva EY; Bowen Z; Hasan MT; Chang TY
Mol Ther; 2013 Aug; 21(8):1497-506. PubMed ID: 23774792
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Trait Locus Mapping of Macrophage Cholesterol Metabolism and CRISPR/Cas9 Editing Implicate an ACAT1 Truncation as a Causal Modifier Variant.
Hai Q; Ritchey B; Robinet P; Alzayed AM; Brubaker G; Zhang J; Smith JD
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):83-91. PubMed ID: 29097366
[TBL] [Abstract][Full Text] [Related]
8. ACAT inhibition and amyloid beta reduction.
Bhattacharyya R; Kovacs DM
Biochim Biophys Acta; 2010 Aug; 1801(8):960-5. PubMed ID: 20398792
[TBL] [Abstract][Full Text] [Related]
9. Triton X-100 or octyl glucoside inactivates acyl-CoA:cholesterol acyltransferase 1 by dissociating it from a two-fold dimer to a two-fold monomer.
Neumann B; Chang CCY; Chang TY
Arch Biochem Biophys; 2019 Aug; 671():103-110. PubMed ID: 31251920
[TBL] [Abstract][Full Text] [Related]
10. Role of acyl-coenzyme a: cholesterol acyltransferase activity in the processing of the amyloid precursor protein.
Puglielli L; Ellis BC; Ingano LA; Kovacs DM
J Mol Neurosci; 2004; 24(1):93-6. PubMed ID: 15314256
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-specific Acat1 ablation attenuates inflammatory responses in macrophages, improves insulin sensitivity, and suppresses diet-induced obesity.
Huang LH; Melton EM; Li H; Sohn P; Jung D; Tsai CY; Ma T; Sano H; Ha H; Friedline RH; Kim JK; Usherwood E; Chang CCY; Chang TY
Am J Physiol Endocrinol Metab; 2018 Sep; 315(3):E340-E356. PubMed ID: 29533741
[TBL] [Abstract][Full Text] [Related]
12. The recent insights into the function of ACAT1: A possible anti-cancer therapeutic target.
Goudarzi A
Life Sci; 2019 Sep; 232():116592. PubMed ID: 31228515
[TBL] [Abstract][Full Text] [Related]
13. Silencing the ACAT1 Gene in Human SH-SY5Y Neuroblastoma Cells Inhibits the Expression of Cyclo-Oxygenase 2 (COX2) and Reduces β-Amyloid-Induced Toxicity Due to Activation of Protein Kinase C (PKC) and ERK.
Chen Y; Zhu L; Ji L; Yang Y; Lu L; Wang X; Zhou G
Med Sci Monit; 2018 Dec; 24():9007-9018. PubMed ID: 30541014
[TBL] [Abstract][Full Text] [Related]
14. Selective ACAT inhibitors as promising antihyperlipidemic, antiathero-sclerotic and anti-Alzheimer drugs.
Giovannoni MP; Piaz VD; Vergelli C; Barlocco D
Mini Rev Med Chem; 2003 Sep; 3(6):576-84. PubMed ID: 12871160
[TBL] [Abstract][Full Text] [Related]
15. Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness.
Lada AT; Davis M; Kent C; Chapman J; Tomoda H; Omura S; Rudel LL
J Lipid Res; 2004 Feb; 45(2):378-86. PubMed ID: 14617738
[TBL] [Abstract][Full Text] [Related]
16. ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia.
Rudel LL; Lee RG; Parini P
Arterioscler Thromb Vasc Biol; 2005 Jun; 25(6):1112-8. PubMed ID: 15831806
[TBL] [Abstract][Full Text] [Related]
17. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD.
Bryleva EY; Rogers MA; Chang CC; Buen F; Harris BT; Rousselet E; Seidah NG; Oddo S; LaFerla FM; Spencer TA; Hickey WF; Chang TY
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3081-6. PubMed ID: 20133765
[TBL] [Abstract][Full Text] [Related]
18. ACAT as a drug target for Alzheimer's disease.
Huttunen HJ; Kovacs DM
Neurodegener Dis; 2008; 5(3-4):212-4. PubMed ID: 18322393
[TBL] [Abstract][Full Text] [Related]
19. Enhanced acyl-CoA:cholesterol acyltransferase activity increases cholesterol levels on the lipid droplet surface and impairs adipocyte function.
Xu Y; Du X; Turner N; Brown AJ; Yang H
J Biol Chem; 2019 Dec; 294(50):19306-19321. PubMed ID: 31727739
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?
López-Farré AJ; Sacristán D; Zamorano-León JJ; San-Martín N; Macaya C
Cardiovasc Ther; 2008; 26(1):65-74. PubMed ID: 18466422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
